Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.56 |
| ▸ | CNR2 | P34972 | 3/20 | 0.51 |
| ▸ | PBK | Q96KB5 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1580724 | 0.92 | GSK3B (0.59) | GSK3BPBKSMN1; SMN2LMNAPOLB | |
| SCHEMBL1581271 | 0.88 | GSK3B (0.67) | GSK3BPBK | |
| SCHEMBL2313528 | 0.86 | PBK (0.55) | GSK3BPBK | |
| SCHEMBL1581204 | 0.85 | ERCC1 (0.55) | GSK3BPBK | |
| SCHEMBL12435383 | 0.84 | GSK3B (0.67) | GSK3BPBK | |
| SCHEMBL2318255 | 0.84 | PBK (0.53) | GSK3BPBK | |
| SCHEMBL1581152 | 0.83 | PBK (0.52) | GSK3BPBKSMN1; SMN2LMNAPOLB | |
| SCHEMBL2313271 | 0.83 | PBK (0.61) | GSK3BPBK | |
| SCHEMBL2312880 | 0.82 | GSK3B (0.53) | GSK3BPBKSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2313936 | 0.81 | GSK3B (0.55) | GSK3BPBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| WO-2010014794-A1 | BENZOIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190351-A1 | Benzoimidazole Derivatives and Glycogen Synthase Kinase-3 Beta Inhibitors Containing the Same | GSK3B, GSK3A, GYS2 | GSK3B 1/4885CNR2 4647/4885PBK 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.